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Pharmacokinetic and Hemodynamic
Responses to Oral Sildenafil During Invasive
Testing in Children With Pulmonary Hypertension
Christian Apitz, MD,*‡ Janette T. Reyes, RN,* Helen Holtby, MD,† Tilman Humpl, MD,*
Andrew N. Redington, MD*
Toronto, Ontario, Canada; and Tübingen, Germany
Objectives The purpose of our study was to characterize the hemodynamic and corresponding pharmacokinetic responses to a
single dose of oral sildenafil by children with pulmonary arterial hypertension (PAH) undergoing invasive testing.
Background Although used frequently for the treatment of children with PAH, data regarding the acute responses to silde-
nafil are limited.
Methods Thirty-six patients (mean age 7.5  5.9 years; 24 females) were studied during cardiac catheterization with gen-
eral anesthesia. Eight of 36 (22%) had idiopathic PAH; the remainder had associated congenital heart disease.
Hemodynamics and serum cyclic-guanosine monophosphate levels (cGMP) were evaluated at baseline and after
inhaled nitric oxide (NO) (40 ppm). In addition, cGMP and sildenafil levels were measured 30 min after adminis-
tration of sildenafil (0.5 mg/kg, suspended in 5 ml sterile water) through a nasogastric tube.
Results For the 36 patients, the pulmonary vasodilating capability of oral sildenafil was lower than that of inhaled NO (2.8%
vs. 11.6% reduction in pulmonary vascular resistance indexed to body surface area [PVRI], respectively; p  0.01).
However, only 21 of 36 (58%) patients had a detectable sildenafil level. In those with detectable sildenafil levels, the
fall in PVRI was greater (11.6% vs. 19.1%, p  NS). Mean cGMP levels at baseline and after NO were 41.8 
20.0 pmol/ml and 83.8  35.5 pmol/ml, respectively (p  0.0001). Surprisingly, there was no significant increase in
cGMP in patients with either undetectable (37.5  29.8 pmol/ml) or detectable (44.4  31.7 pmol/ml) sildenafil
levels (p  NS compared with baseline) with sildenafil.
Conclusions Our study demonstrates suboptimal absorption of sildenafil in almost half the children undergoing acute hemody-
namic testing. When detectable, there was no statistically significant difference between the fall in PVRI associated
with sildenafil and NO despite lower circulating cGMP levels in the sildenafil group. These data should be taken into
account when designing acute testing protocols, and assessing the acute response to sildenafil in patients with
PAH. (J Am Coll Cardiol 2010;55:1456–62) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.065r
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wcute administration of a single oral dose of sildenafil to
dults with pulmonary hypertension causes a significant
ecrease in mean pulmonary artery pressure (mPAP) and
ulmonary vascular resistance (PVR) (1,2), and its utility in
hronic therapy is now established (3,4).
The effectiveness of sildenafil as a pulmonary vasodilator
n children with congenital heart disease (CHD) was first
rom the Divisions of *Cardiology and †Cardiac Anaesthesia, Hospital for Sick
hildren, University of Toronto, Toronto, Ontario, Canada; and the ‡Division of
ardiology, University Children’s Hospital, Tübingen, Germany. The study was
upported by the Innovations Fund of the Labatt Family Centre, Toronto, Canada.
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rankfurt, Germany. Dr. Humpl is an advisor/consultant for Pfizer and Actelion.
rs. Humpl and Redington are joint senior authors.n
Manuscript received August 18, 2009; revised manuscript received November 6,
009, accepted November 23, 2009.eported in a small case series post-operatively in 1999 (5),
nd confirmed 4 years later in the first detailed prospective
pen-label study during cardiac catheterization and post-
peratively (6). Using an intravenous preparation in that
tudy, the authors were able to show a similar acute
emodynamic response to that of inhaled nitric oxide (NO),
nd a direct relationship between cyclic-guanosine mono-
hosphate (cGMP) level and therapeutic response. Al-
hough sildenafil is now used frequently for long-term
reatment of children with pulmonary arterial hypertension
7), clinical data regarding the acute pharmacokinetic and
emodynamic responses to sildenafil are limited.
Therefore, the purpose of this study was to characterize
he responses to fixed dosing of oral sildenafil for children
ith pulmonary hypertension undergoing invasive hemody-
amic testing in the catheterization laboratory.
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he study design was open label, prospective, and interven-
ional. The study protocol was approved by the research and
thics review board of the Hospital for Sick Children,
oronto, Canada, and informed signed consent was ob-
ained from the study subjects and their parents.
rotocol. All patients undergoing cardiac catheterization
o assess pulmonary hypertension, defined as mean pulmo-
ary arterial pressure (mPAP) 25 mm Hg or pulmonary
ascular resistance index (PVRI) 5 Wood units (WU),
ndexed for body surface area (BSA), were eligible for
nclusion. These patients routinely undergo pulmonary vas-
ular reactivity drug testing in the cardiac catheterization
aboratory before decisions about therapy. We excluded
atients with hepatic or renal insufficiency and known
etinal disease.
Patients were studied under general anesthesia with
echanical ventilation with a baseline fraction of inspired
xygen (FiO2) of 0.25 (if not required to be higher for
linical reasons). Anesthesia was induced with sevoflurane,
idazolam, and remifentanil. Sevoflurane was discontinued
fter induction. Rocuronium was used for muscle relaxation.
nasogastric tube was placed, and its position confirmed by
uoroscopy. Measurement of baseline hemodynamics in-
luded arterial and venous saturations, blood gases, systemic
nd pulmonary artery pressures, left atrial (or pulmonary
apillary wedge) pressure, and right atrial pressure in the
tandard manner with fluid-filled catheters. End-tidal car-
on dioxide and systemic oxygen consumption were con-
inuously determined using respiratory mass spectrometry.
xygen saturations were measured by co-oximetry after
ampling in the superior vena cava, pulmonary vein, pulmo-
ary artery, and systemic artery. We estimated systemic and
ulmonary blood flows from the Fick equation. We calcu-
ated systemic and PVRs from standard equations (mean
rterial pressure minus mean atrial pressure divided by flow).
lood flow and vascular resistances were indexed to BSA.
Assessment of pulmonary vascular reactivity was under-
aken as follows: measurements were made at baseline (at
usual” FiO2) and with FiO2 0.7 (if higher than usual
equirements). The patients were then returned to baseline
iO2, and after 10 min, the effect of additional inhaled NO
t 40 ppm for 10 min was recorded. The NO was then
iscontinued, and new baseline hemodynamics were mea-
ured after 10 min. Subsequently, a dose of sildenafil (0.5
g/kg, suspended in 5 ml sterile water) was administered
hrough the nasogastric tube. Measurements were repeated
t 30 min.
For the determination of sildenafil and cGMP levels,
lood samples of each patient were taken from the pulmo-
ary artery and were then transferred to heparinized
olypropylene tubes and centrifuged for 10 min at 4,000
pm; the supernatant plasma was pipetted into screw-
apped polypropylene tubes and stored at80oC, within 50
in of blood sample collection. Measurements of cGMP sevels were recorded at baseline,
fter 10 min of inhaled NO, and
efore and 30 min after admin-
stration of sildenafil. Plasma
amples were analyzed using a
ommercially available enzyme
mmunoassay (Amersham cGMP,
E Healthcare UK Ltd., Buck-
nghamshire, United Kingdom).
he sildenafil level was measured
0 min after oral administration of
ildenafil. The quantitative analyses
or sildenafil and its N-desmethyl
etabolite were performed at NMS
abs, Willow Grove, Pennsylvania,
sing high-performance liquid chro-
atography with tandem mass
pectrometry.
The primary outcome measure
as the PVRI and the mPAP at
ardiac catheterization. A signif-
cant acute response to NO and/or sildenafil was defined as
fall in mPAP and/or PVRI of at least 20% relative to the
aseline value (8). The secondary outcome measure was the
GMP level at baseline, after NO, and after sildenafil, as
ell as the sildenafil level 30 min after oral administration.
ata analysis. Data are presented as mean and standard
eviation. Comparisons were performed by nonparametric
ann-Whitney test if the sample groups were not paired,
or example, comparison between patients with idiopathic
nd PAH associated with CHD, or the comparison be-
ween responders and nonresponders. Paired t tests were
tilized to compare the hemodynamic parameters after each
ntervention to the corresponding baseline value of each
atient and to evaluate differences of the effect on PVR of
O and sildenafil.
We used a linear regression test to examine the correla-
ion between plasma sildenafil concentration and cGMP
evels, and fall in PVRI, respectively. Analysis was per-
ormed using GraphPad statistical software package (San
iego, California). The null hypothesis was rejected when
 0.05.
esults
atient population. Thirty-six patients (mean age 7.5 
.9 years; 24 females) fulfilled entry criteria and were
nrolled in the study protocol. The clinical characteristics of
he patients are outlined in Table 1. The diagnosis was
diopathic pulmonary hypertension in 8 of 36 (22%) pa-
ients, and 28 (78%) patients had associated CHD. At
aseline, the mPAP was 46.4  18.2 mm Hg, and the
VRI was 16.5  10.8 WU  m2 BSA.
emodynamic parameters. Mean pulmonary artery pres-
Abbreviations
and Acronyms
BSA  body surface area
cGMP  cyclic-guanosine
monophosphate
CHD  congenital heart
disease
FiO2  fraction of inspired
oxygen
mPAP  mean pulmonary
arterial pressure
NO  nitric oxide
PAH  pulmonary arterial
hypertension
PVR  pulmonary vascular
resistance
PVRI  pulmonary vascular
resistance index
WU  Wood unitsure decreased with hyperoxia from 46.4  18.2 mm Hg to
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6.5  18.2 mm Hg to 43.9  17.9 mm Hg (p  0.01).
here was a nonsignificant fall in mPAP after administra-
ion of oral sildenafil (46.1  18.4 mm Hg to 44.9  18.7
m Hg). Pulmonary vascular resistance decreased with
yperoxia from 16.5  10.8 WU  m2 BSA to 12.9  8.1
U  m2 BSA (p  0.002) and with inhaled NO from
6.4  10.2 WU  m2 BSA to 14.8  10.4 WU  m2
SA (p  0.01). With sildenafil, there was a nonsignificant
all in mean PVR from 15.5 10.0 WUm2 BSA to 15.1
11.2 WU  m2 BSA. For all 36 patients, the pulmonary
asodilation 30 min after oral sildenafil was lower than that
ith inhaled NO (2.8  26.7% vs. 11.6  23.5% PVRI
eduction, p 0.01) (Fig. 1A). However, using the criteria of
ich et al. (8), 31% of patients had a significant hemodynamic
atient CharacteristicsTable 1 Patient Characteristics
Patient # Sex Diagnosis
Age
(yrs)
BSA
(m2)
Weight
(kg)
mPAP
(mm Hg)
PVRI
(WU  m2 BSA)
1 F CHD/repaired 9.08 1.10 32.0 25 8.13
2 M Idiopathic PH 13.5 1.14 30.4 51 13.02
3 F CHD 0.42 0.21 3.4 47 30.70
4 F Idiopathic PH 17.08 1.68 65.6 80 20.47
5 F CHD 1.25 0.35 7.2 28 7.44
6 F CHD/repaired 10.25 0.94 23.5 61 20.16
7 F CHD 16.83 1.71 59.8 58 12.82
8 M CHD 0.5 0.20 3.6 24 9.04
9 F CHD 1.83 0.44 9.3 14 5.22
10 F Idiopathic PH 0.5 0.27 4.9 29 10.20
11 M CHD/repaired 3.83 0.65 16.6 19 7.14
12 M Idiopathic PH 16 2.40 117.0 80 19.68
13 M CHD 2.08 0.49 10.6 59 14.22
14 F CHD 7 0.84 21.0 36 9.19
15 M CHD 1.25 0.43 9.2 42 7.63
16 F CHD 3.5 0.54 12.0 44 11.60
17 F CHD 11.58 1.17 35.7 68 32.68
18 M Idiopathic PH 1.42 0.50 11.2 26 7.61
19 M CHD/repaired 4 0.55 12.1 35 8.54
20 F CHD/repaired 7.42 0.96 33.0 43 28.38
21 F Idiopathic PH 8.66 0.96 24.6 38 4.99
22 F CHD/repaired 5.5 0.94 26.7 42 18.55
23 F CHD 14.58 1.46 54.3 76 47.32
24 M CHD 16.58 1.35 42.5 54 40.95
25 F CHD/repaired 12.67 0.99 27.2 12 5.09
26 F CHD 5.58 1.03 30.5 64 20.80
27 M Idiopathic PH 12.83 1.13 32.3 61 33.40
28 F CHD/repaired 17.42 1.70 59.4 61 30.00
29 F CHD 2 0.35 6.9 52 13.30
30 M CHD 1.33 0.38 9.0 47 19.50
31 F CHD/repaired 1.83 0.45 10.0 21 7.21
32 F CHD 11 1.12 35.1 54 17.60
33 F CHD/repaired 9.33 0.96 25.4 42 8.67
34 F Idiopathic PH 15.42 1.71 66.8 64 23.27
35 M CHD 0.42 0.22 3.3 61 12.59
36 F CHD 7.08 0.85 21.3 52 6.83
SA  body surface area; CHD  congenital heart disease; mPAP  mean pulmonary arterial
ressure; PH  pulmonary hypertension; PVRI  pulmonary vascular resistance index.esponse to NO (n  11), and 28% to sildenafil (n  10).ildenafil and cGMP levels. Fifteen of 36 (42%) patients
ad a sildenafil level below the lower threshold for quanti-
cation (1.2 ng/ml). Furthermore, 24 of 36 (76%) patients
ad a desmethylsildenafil level below the lower limit of
uantification (1.2 ng/ml). The mean plasma concentra-
ion of desmethylsildenafil in patients with detectable levels
as 41.7  32.4 ng/ml. The mean plasma concentration of
ildenafil in those with detectable levels was 69.3  104.9
g/ml, and 9 of 21 (43%) were responders. In patients with
etectable sildenafil levels, the pulmonary vasodilating ca-
ability of oral sildenafil was not statistically significantly
ifferent from inhaled NO (11.6  23.2% vs. 19.1 
8.9%, p  NS) (Fig. 1B). In patients with an undetectable
ildenafil level, there was no detectable pulmonary vasodi-
ating capability 30 min after administration of sildenafil
9.4  27.1%, p  NS).
Figure 1
Percentage of Reduction in PVR Caused by
Inhalation of NO 40 ppm and After Administration
of Oral Sildenafil
(A) Bar graph showing mean and SEM: for all 36 patients, the pulmonary vaso-
dilation 30 min after oral sildenafil (shaded bar) was lower than that for
inhaled nitric oxide (NO) (solid bar), 2.8% versus 11.6% pulmonary vascu-
lar resistance (PVR) reduction (p  0.01). (B) In patients with detectable silde-
nafil levels (n  21), the pulmonary vasodilating capability of oral sildenafil
(shaded bar) was not significantly different from that of inhaled NO (solid bar),
11.6% versus 19.1% (p  NS).
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April 6, 2010:1456–62 Acute Sildenafil Response by Children With Pulmonary HypertensionComparing sildenafil responders and nonresponders, the
eduction of PVRI with NO was 30.5  20.2% in
esponders versus 4.3  20.7% in nonresponders, and
ith sildenafil, it was 29.6  18.5% in responders versus
7.4  21.8% in nonresponders (p  0.0001, for both
omparisons). In terms of absolute measurements, the PVRI
efore and after sildenafil in the responders was 15.2  8.9
U  m2 and 10.8  6.9 WU  m2 (p  0.003), and in
he nonresponders it was 15.5  10.6 WU  m2 and 16.8 
2.2 WU  m2 (p  NS).
Mean cGMP levels at baseline and after NO were 41.8
0.0 pmol/ml and 83.8  35.5 pmol/ml, respectively (p 
.0001) (Fig. 2A). Comparing sildenafil responders and
onresponders, we realized higher cGMP levels with NO
nd a significantly steeper decline after withdrawal of NO in
ildenafil nonresponders (p  0.0001) (Figs. 2B and 2C).
Surprisingly, there was no increase in cGMP with silde-
afil in either patients with undetectable (37.5  29.8
mol/ml) or detectable (44.4  31.7 pmol/ml) sildenafil
evels (pNS compared with baseline). Nonetheless, in the
atter group, there was a weak correlation between sildenafil
evel and fall in PVRI (r  0.41; p  0.06) (Fig. 3A) and
etween sildenafil and cGMP levels (r  0.5; p  0.02)
Fig. 3B).
diopathic PAH versus PAH associated with CHD.
omparing patients with idiopathic PAH to those with PAH
ssociated with CHD, we found higher sildenafil levels in
atients with idiopathic PAH (151.02 179.5 ng/ml vs. 43.8
6.2 ng/ml; p  0.04), whereas a positive response was more
requently seen in patients with PAH associated with CHD
32% vs. 13%). There was no significant difference in the
GMP response between the 2 patient groups.
iscussion
his study is the first to detail the hemodynamic and
harmacokinetic responses to enterally administered silde-
afil by children undergoing acute pulmonary vasodilator
esting. The accurate assessment of PAH and its response to
herapy is a critical component of management of children
ith and without associated structural heart disease. Inva-
ive hemodynamic testing in the catheterization laboratory,
sually employing general anesthesia in younger infants,
emains the gold standard for diagnosis, assessment of
rognosis, and guidance of long-term therapy (9). Testing
rotocols vary, but most include evaluation of pulmonary
ascular responsiveness to “selective” pulmonary vasodila-
ors, such as oxygen and NO and prostacyclin (10–12).
hile not being advised by international guidelines because
f the absence of published data on its utility as a predictor
f calcium-channel blocker response, there are several stud-
es assessing the acute effects of orally administrated silde-
afil in adults with pulmonary hypertension (2,13–16).
lthough the drug is almost universally effective hemodynam-
cally, few studies relate these responses to the measured levels
f plasma sildenafil or cGMP. The data are even more limited lor children. However, a direct relationship between cGMP
evels and hemodynamic response was shown in response to
oth inhaled NO and sildenafil administered intravenously to
hildren undergoing testing in the cardiac catheterization
Figure 2 Pulmonary Arterial cGMP Levels at Baseline
and in Response to iNO and Oral Sildenafil
(A) Mean cyclic-guanosine monophosphate (cGMP) levels ( SEM) of all
patients at baseline and after inhaled nitric oxide (iNO) were 41.8  3.3
pmol/ml and 83.8  5.9 pmol/ml, respectively (p  0.0001). There was no
increase in cGMP with sildenafil (p  NS compared with baseline). (B) Mean
cGMP levels of patients without significant hemodynamic response to sildenafil
(nonresponder). (C) Mean cGMP levels of patients with a significant hemody-
namic response to sildenafil (responder). A significantly steeper decline is dem-
onstrated after withdrawal of NO in sildenafil nonresponders (B) compared with
sildenafil responders (C).aboratory in a previous study from members of our group (6),
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Acute Sildenafil Response by Children With Pulmonary Hypertension April 6, 2010:1456–62nd recently some centers have introduced oral sildenafil as an
lternative to inhaled NO to test pre-operative operability in
hildren with congenital heart defects (17). We believe it is
imely, therefore, to document the responses to enteral silde-
afil in children undergoing cardiac catheterization.
harmacokinetics. In the current study, we investigated
ot only the acute hemodynamic effects of a single oral dose
f sildenafil, but also its corresponding pharmacokinetics in
hildren. When administered orally in capsule form to adult
olunteers, the peak plasma level of sildenafil is seen after 45
o 60 min (18), and this time frame coincides with its
linical effects in patients (13,19). However, pre-clinical
tudies in juvenile lambs (weighing 16 to 25 kg) have shown
he onset of pulmonary vasodilation to occur within 5 min,
nd maximal vasodilation (with coincident plasma sildenafil
evels of 28.8  9.9 ng/ml) to occur 15 min after adminis-
Figure 3 Correlation of Sildenafil Levels
With PVRI Fall and cGMP Levels
(A) Correlation of sildenafil levels with fall in pulmonary vascular resistance
index (PVRI), and (B) correlation of sildenafil levels with cyclic-guanosine mono-
phosphate (cGMP) levels 30 min after administration in all patients with detect-
able sildenafil level. There was a weak correlation between sildenafil level and
fall in PVRI (r  0.41; p  0.06) and between sildenafil and cGMP levels (r 
0.5; p  0.02).ration of sildenafil suspension through a nasogastric tube h20). Similarly, after administration as a suspension through
nasogastric tube, an almost immediate hemodynamic
esponse to sildenafil has been reported in infants with PAH
21). In the only previous study of sildenafil levels in
hildren with PAH, Karatza et al. (22) reported mean levels
f 109  87 ng/ml 1 h after oral administration in 3
atients. These data are difficult to interpret for the follow-
ng reasons: individual levels were not given, but there was
learly a wide range, given the standard error of the mean;
sildenafil level was not measured earlier than 1 h after
dministration; and not only was sildenafil administered
rally, but also the exact mode of delivery (tablet/capsule/
uspension) was not detailed.
Given these data, and with the aim to minimize the
uration of general anesthesia in these often hemodynam-
cally challenged patients, we chose to measure the effects
nd levels of sildenafil 30 min after administration as a
uspension through nasogastric tube. However, our study
emonstrates that in the clinical situation, the absorption of
ildenafil 30 min after administration through nasogastric
ube is quite unpredictable. Indeed, the plasma sildenafil
evel was undetectable in almost one-half the children, and
anged from 1.2 to 460 ng/ml in those in whom it could be
easured. Furthermore, the levels of the N-desmethyl
etabolite were also low, suggesting that rapid absorption
nd conversion by hepatic metabolism was not implicated.
here are many other potential causes for these findings,
ncluding the use of general anesthesia, opiate analgesia, and
ransient neuromuscular blockade, all of which may all
odify gastric emptying and thus absorption from the
astrointestinal tract. No matter what the cause, these data
ave important implications for the assessment of effect, and
uture protocols of use, of enterally administered sildenafil
n children undergoing vasodilator testing.
emodynamic effect of oral sildenafil. In the absence of
he pharmacokinetic data, the hemodynamic response to
ildenafil in our total population would appear to be
isappointing. However, our results show that when there
as a detectable serum level, there was no statistically
ignificant difference in reduction of elevated PVR when
ildenafil was compared with inhaled NO. However, the
umber of patients is relatively small, and with a larger
ample size, the trend toward superiority of NO might
ecome significant. Nevertheless, this observation is in
greement with our previous report of the effects of intra-
enously administered sildenafil (6). Furthermore, in 3 of
ur patients, there was a response to sildenafil, despite a lack
f response to 40-ppm NO. These findings may have
mportant prognostic and therapeutic implications for the
ndividual patient with pulmonary hypertension and are in
greement with similar observations in a previous report of
ildenafil effects in adults with PAH (2). In this context, it
s of note that when we tested the long-term effects of
ildenafil in children with PAH, we found 9 of 14 patients
ad improved pulmonary hemodynamics at follow-up de-
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April 6, 2010:1456–62 Acute Sildenafil Response by Children With Pulmonary Hypertensionpite the absence of an acute response to inhaled NO during
he primary vasoreactivity testing (7).
Perhaps more unexpected was the finding that a signifi-
ant reduction in PVRI was observed in patients with an
ndetectable level of sildenafil. The reasons for this are
nclear. While it is possible that there could be bias in data
ollection, as the operators were not blinded to treatments
s in a randomized trial, this was minimized by the rigid
ime-based protocol that governed hemodynamic data col-
ection, and the fact that changes in blood gas concentra-
ions and oxygen consumption cannot be predicted by the
perator and form important elements to the ultimate PVR
alculation that was calculated off line. Furthermore, our
tudy was not designed to be, and cannot be interpreted as,
dose-response study. However, this finding does suggest
hat the therapeutic range for sildenafil might be wider than
reviously thought, at least for some patients with PAH.
evels of cGMP and responses. The major unexpected
nding of our study was the lack of a significant change in
GMP levels both in the group with and in the group
ithout measurable sildenafil levels, and largely irrespective
f hemodynamic response. In patients with detectable levels
f sildenafil, the fall in PVRI was similar to that observed
ith inhaled NO. There was a marked difference in cGMP
esponses, however. With inhaled NO, there was a highly
ignificant rise in cGMP levels, whereas there was no
hange with sildenafil. While there was a loose, and statis-
ically significant, relationship between both sildenafil and
GMP levels and the degree of response of PVRI, the levels
f cGMP were markedly lower than that observed with
nhaled NO in the same patients. This finding clearly
uggests a difference in response or mechanism of action (in
erms of cGMP effects) between sildenafil and NO. In a
revious study of 13 adult patients (69% idiopathic pulmo-
ary hypertension) Michelakis et al. (2) observed equal
otency of oral sildenafil and inhaled NO despite a lower
GMP response to sildenafil (24 pmol/ml vs. 35 pmol/ml),
lthough, interestingly, they were unable to show a corre-
ation between cGMP level and reduction of PVR.
There are several possible explanations for these, and our,
ndings. First, given the nature of our protocol, it is possible
hat sildenafil was administered before the full effects of
nhaled NO were dissipated. Although there was a period of
0 min between cessation of NO inhalation and sildenafil
dministration (ample time for the direct effect of NO to
ave been lost), it is possible that circulating cGMP levels
emained raised. However, not only would it be highly
nlikely that sufficient absorption of sildenafil could influ-
nce the further decline in cGMP levels early after with-
rawal of NO, but also a further 30 min elapsed before the
otential effects of sildenafil were then assessed. Given also
hat there was no difference in cGMP levels between the
esponders and nonresponders, this makes an interaction
etween NO and sildenafil as an explanation for fall in PVR
een with sildenafil in the absence of measurable levels
nlikely, but it cannot be excluded. It is also possible thatystemic levels of cGMP do not reflect intracellular cGMP
evels within the vascular smooth muscle, given the direct
nd indirect (through phosphodiesterase type 5) effects of
nhaled NO and sildenafil, respectively. Going along with
his, and touched upon earlier, the therapeutic response to
ildenafil may be different to that of inhaled NO, and may
ary from person to person, in a less predictable way to that
f NO. It is known for example that different disease states
ead to different effects on the levels and function of
ntracellular phosphodiesterase type 5 itself (23). Finally,
here may be a hitherto undescribed mechanism of action of
ildenafil in PAH that is not associated with the classical
O-cGMP pathway. Our study was not designed to
ddress these possibilities, and clearly more studies are
eeded to define the pharmacokinetics, dose response, and
echanisms of actions of sildenafil in these patients.
onclusions
ur study demonstrates suboptimal absorption of sildenafil
n almost half the children undergoing acute hemodynamic
esting. When detectable, the effect of sildenafil on pulmo-
ary vasodilation was not significantly different from that of
nhaled NO despite marked differences in cGMP levels,
mplying differences in response or mechanism of action of
he 2 therapies. Finally, response to sildenafil was also
ocumented despite undetectable levels, suggesting the
herapeutic range for some children might be wider than
reviously described for adults.
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